We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Correction: Novartis Reports Success in Trials of Three Different Therapies
Correction: Novartis Reports Success in Trials of Three Different Therapies
December 14, 2015
Novartis reported that its Phase 2 study of CTL019, its investigational chimeric antigen receptor T cell therapy, found that 55 of 59 (93%) pediatric patients with relapsed/refractory acute lymphoblastic leukemia experienced complete remissions. Drug Industry Daily misstated the patient population.